Cantargia AB: Studies Using Cantargia's Antibodies in Models of Chronic Myeloid Leukaemia Presented at the American Society of Hematology

Results generated using Cantargia AB’s (”Cantargia”) antibodies, including the product candidate CAN04, are to be presented by Dr Helena Ågerstam of Lund University in an oral session at the American Society of Hematology's (ASH) 58th annual meeting in San Diego on 3-6 December 2016. The presentation focuses on studies in preclinical models of chronic myeloid leukaemia (CML).

Cantargia develops the humanised antibody CAN04 against the target molecule Interleukin-1 Receptor Associated Protein (IL1RAP) for the treatment of cancer. Cantargia has previously shown that antibodies targeted against IL1RAP are able to stimulate the killing of tumour cells in various preclinical cancer models. The data presented are based on the study that was published in September 2016 in the scientific journal Blood (http://www.bloodjournal.org/content/early/2016/09/12/blood-2015-11-679985). Data show that IL1RAP is an interesting and relevant target for antibody treatment of CML and also adds important knowledge that can be used in CAN04 treatment of other cancer forms characterised by IL1RAP overexpression.

”We are very pleased that the results from studies involving Cantargia's antibodies have attracted so much attention and thus have been selected for an oral presentation at a leading scientific conference in the field of haematology”, says Göran Forsberg, CEO at Cantargia. ”It confirms that our project is being followed with interest and have raised the profile of Cantargia at an international level.”

The results are being presented on December 5th at 2.45 p.m. local time. An abstract is available at http://www.hematology.org/Annual-Meeting.

This information is of such a nature that Cantargia is obliged to publish it in accordance with the EU's regulation on market abuse. Information has been provided, through the agency of the above contact person, for publication on 3 November 2016 at 15.00.

This information was brought to you by Cision http://news.cision.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20161103006034/en/